CN103189055A - 用于缓解阿片类物质用药过量引起的呼吸抑制的制剂和方法 - Google Patents

用于缓解阿片类物质用药过量引起的呼吸抑制的制剂和方法 Download PDF

Info

Publication number
CN103189055A
CN103189055A CN201180051633XA CN201180051633A CN103189055A CN 103189055 A CN103189055 A CN 103189055A CN 201180051633X A CN201180051633X A CN 201180051633XA CN 201180051633 A CN201180051633 A CN 201180051633A CN 103189055 A CN103189055 A CN 103189055A
Authority
CN
China
Prior art keywords
naltrexone
opioid
preparation
oxycodone
respiration inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201180051633XA
Other languages
English (en)
Chinese (zh)
Inventor
M·J.·拉姆森
V·戈利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpharma Pharmaceuticals LLC
Original Assignee
Alpharma Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpharma Pharmaceuticals LLC filed Critical Alpharma Pharmaceuticals LLC
Publication of CN103189055A publication Critical patent/CN103189055A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201180051633XA 2010-10-26 2011-10-25 用于缓解阿片类物质用药过量引起的呼吸抑制的制剂和方法 Pending CN103189055A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40675210P 2010-10-26 2010-10-26
US61/406,752 2010-10-26
PCT/IB2011/054767 WO2012056402A2 (en) 2010-10-26 2011-10-25 Formulations and methods for attenuating respiratory depression induced by opioid overdose

Publications (1)

Publication Number Publication Date
CN103189055A true CN103189055A (zh) 2013-07-03

Family

ID=45470606

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180051633XA Pending CN103189055A (zh) 2010-10-26 2011-10-25 用于缓解阿片类物质用药过量引起的呼吸抑制的制剂和方法

Country Status (14)

Country Link
US (3) US20140030343A1 (enExample)
EP (1) EP2632442A2 (enExample)
JP (1) JP2013540807A (enExample)
KR (3) KR20160017668A (enExample)
CN (1) CN103189055A (enExample)
AU (1) AU2011322147A1 (enExample)
BR (1) BR112013009267A2 (enExample)
CA (1) CA2814230A1 (enExample)
IL (1) IL225966A0 (enExample)
MX (1) MX2013003832A (enExample)
RU (1) RU2541159C2 (enExample)
SG (1) SG189234A1 (enExample)
WO (1) WO2012056402A2 (enExample)
ZA (1) ZA201302363B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1299104T1 (sl) 2000-02-08 2009-10-31 Euro Celtique Sa Oralne formulacije opioidnih agonistov, varne pred zlorabo
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
CA2814230A1 (en) * 2010-10-26 2012-05-03 Alpharma Pharmaceuticals, Llc Formulations and methods for attenuating respiratory depression induced by opioid overdose
EP2670400A1 (en) * 2011-02-02 2013-12-11 Alpharma Pharmaceuticals LLC Pharmaceutical composition comprising opioid agonist and sequestered antagonist
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
KR102688278B1 (ko) 2015-12-22 2024-07-26 조게닉스 인터내셔널 리미티드 펜플루라민 조성물 및 그 제조 방법
JP2019507111A (ja) 2015-12-22 2019-03-14 ゾゲニクス インターナショナル リミテッド 代謝抵抗性フェンフルラミン類縁体およびその使用法
US10766925B2 (en) * 2016-04-11 2020-09-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Opioid receptor modulators
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
CA3032996C (en) 2016-08-24 2025-05-06 Zogenix International Ltd Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
IL273627B2 (en) 2017-12-20 2025-03-01 Purdue Pharma Lp Morphine sulfate dosage forms for abuse deterrence
CA3097335A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
WO2019241005A1 (en) 2018-06-14 2019-12-19 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
AU2019384963B2 (en) 2018-11-19 2022-05-26 Zogenix International Limited Methods of treating Rett syndrome using fenfluramine
WO2021072055A1 (en) * 2019-10-11 2021-04-15 Board Of Regents, The University Of Texas System Compositions and methods for preventing, reducing and reversing opioid-induced respiratory depression
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
WO2023081185A1 (en) * 2021-11-02 2023-05-11 Enalare Therapeutics Inc. Methods of treating respiratory depression modulated by a non-opioid agent
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100152221A1 (en) * 2007-12-17 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7914818B2 (en) * 2001-08-06 2011-03-29 Purdue Pharma L.P. Opioid agonist formulations with releasable and sequestered antagonist
CN1901954B (zh) * 2003-12-05 2013-01-16 康尔福盛303有限公司 借助病人监测系统的病人自控镇痛技术
CN101321686A (zh) 2005-10-07 2008-12-10 佛罗里达大学研究基金会有限公司 用于多路信号传递和光编码的多组分纳米颗粒
AU2007322269A1 (en) * 2006-10-11 2008-05-29 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
AU2008296905A1 (en) * 2007-09-04 2009-03-12 Alpharma Pharmaceuticals, Llc A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
CA2709905A1 (en) * 2007-12-17 2009-06-25 Alfred Liang Abuse-resistant oxycodone composition
BRPI0911715A2 (pt) 2008-07-31 2019-09-24 Alma Mater Studiorum - Universita' Di Bologna partículas ativas para aplicações bio-analíticas e métodos para sua preparação.
IT1391530B1 (it) 2008-07-31 2012-01-11 Cyanagen S R L Particelle attive per applicazioni bio-analitiche e metodi per la loro preparazione
CA2814230A1 (en) * 2010-10-26 2012-05-03 Alpharma Pharmaceuticals, Llc Formulations and methods for attenuating respiratory depression induced by opioid overdose

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100152221A1 (en) * 2007-12-17 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WILLIAM T.DENMAN ETAL: "A Randomized Double-Blind Study of the Effects of Oral Naltrexone on Respiratory Drive Induced by 15-25mg of Immediate-Release Oral Hydrocodone", 《ANESTHESIOLOGY》 *

Also Published As

Publication number Publication date
CA2814230A1 (en) 2012-05-03
KR20170102571A (ko) 2017-09-11
WO2012056402A3 (en) 2012-10-04
US20140030343A1 (en) 2014-01-30
ZA201302363B (en) 2014-06-25
JP2013540807A (ja) 2013-11-07
US20160045449A1 (en) 2016-02-18
KR20160017668A (ko) 2016-02-16
SG189234A1 (en) 2013-05-31
RU2013117274A (ru) 2014-12-10
KR20130097211A (ko) 2013-09-02
US20170367987A1 (en) 2017-12-28
IL225966A0 (en) 2013-06-27
BR112013009267A2 (pt) 2016-07-26
RU2541159C2 (ru) 2015-02-10
WO2012056402A2 (en) 2012-05-03
AU2011322147A1 (en) 2013-04-18
MX2013003832A (es) 2013-10-01
EP2632442A2 (en) 2013-09-04

Similar Documents

Publication Publication Date Title
CN103189055A (zh) 用于缓解阿片类物质用药过量引起的呼吸抑制的制剂和方法
US7034036B2 (en) Inhibitors of ABC drug transporters at the blood-brain barrier
US8623418B2 (en) Pharmaceutical composition
US20030191147A1 (en) Opioid antagonist compositions and dosage forms
EP1284736A2 (en) Opioid antagonist compositions and dosage forms
US20150104519A1 (en) Pharmaceutical Compositions
AU2001259458A1 (en) Opioid antagonist compositions and dosage forms
AU2018232854B2 (en) Novel dosage form
AU2008338439A1 (en) Pharmaceutical composition
AU2019201397A1 (en) Formulations and methods for attenuating respiratory depression induced by opioid overdose
HK1186970A (en) Formulations and methods for attenuating respiratory depression induced by opioid overdose
CA3068036A1 (en) Use to buprenorphine in combination with an opioid to treat pain
AU2014216032B2 (en) Pharmaceutical composition
AU2019202760A1 (en) Pharmaceutical composition
CA2427330A1 (en) Inhibitors of abc drug transporters at the blood-brain barrier
AU2014216026A1 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1186970

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130703

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1186970

Country of ref document: HK